932731-59-4 Usage
General Description
6-chloro-8-iodo-9-methyl-9H-purine is a chemical compound with the molecular formula C6H4ClIN4. It is a purine derivative with a chloro, iodo, and methyl substituent on the 6, 8, and 9 positions, respectively, of the purine ring structure. 6-chloro-8-iodo-9-methyl-9H-purine is of interest in medicinal and pharmaceutical research due to its potential biological activities and pharmacological properties. It may have applications in the development of new drugs or as a reference compound in analytical chemistry. Additionally, it can also be used as a building block in organic synthesis for creating more complex molecules with specific structural features. However, more research is needed to fully understand the potential uses and properties of 6-chloro-8-iodo-9-methyl-9H-purine.
Check Digit Verification of cas no
The CAS Registry Mumber 932731-59-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,2,7,3 and 1 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 932731-59:
(8*9)+(7*3)+(6*2)+(5*7)+(4*3)+(3*1)+(2*5)+(1*9)=174
174 % 10 = 4
So 932731-59-4 is a valid CAS Registry Number.
932731-59-4Relevant articles and documents
Projected Dose Optimization of Amino- And Hydroxypyrrolidine Purine PI3KδImmunomodulators
Methot, Joey L.,Zhou, Hua,McGowan, Meredeth A.,Anthony, Neville John,Christopher, Matthew,Garcia, Yudith,Achab, Abdelghani,Lipford, Kathryn,Trotter, Benjamin Wesley,Altman, Michael D.,Fradera, Xavier,Lesburg, Charles A.,Li, Chaomin,Alves, Stephen,Chappell, Craig P.,Jain, Renu,Mangado, Ruban,Pinheiro, Elaine,Williams, Sybill M. G.,Goldenblatt, Peter,Hill, Armetta,Shaffer, Lynsey,Chen, Dapeng,Tong, Vincent,McLeod, Robbie L.,Lee, Hyun-Hee,Yu, Hongshi,Shah, Sanjiv,Katz, Jason D.
, p. 5137 - 5156 (2021/05/04)
The approvals of idelalisib and duvelisib have validated PI3Kδinhibitors for the treatment for hematological malignancies driven by the PI3K/AKT pathway. Our program led to the identification of structurally distinct heterocycloalkyl purine inhibitors wit
